Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Danaher Corp

Other names: Abcam | Epitomics | AxioMx | Abcam Plc | Epitomics, Inc. | AxioMx, Inc. | GE Healthcare Life Sciences | Cytiva | OncoMark | Danaher Corporation | Cepheid | Copper Merger Sub, Inc. | IRIS International, Inc | Iris Molecular Diagnostics | IRIS International | Leica Biosystems | Beckman Coulter Inc | Immunotech | Diagnostic Systems Laboratories | Aldevron | Aldevron, LLC | Beckman Coulter, Inc.
Related tests:


Danaher completes acquisition of Abcam (Danaher Press Release)
"Danaher Corporation...announced today it has completed its acquisition of Abcam plc...The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the 'Scheme') and the Scheme became effective in accordance with its terms on December 6, 2023."
Cepheid receives CE mark for Xpert® NPM1 mutation (PRNewswire)
"Cepheid announced today that it has received the CE mark for Xpert NPM1 Mutation, a molecular in vitro diagnostic test for the quantification of mutant NPM1 mRNA transcripts (types A, B and D in exon 12) in peripheral blood specimens from patients with Acute Myeloid Leukemia (AML). The test utilizes automated real-time reverse transcription polymerase chain reaction (RT-PCR) and reports the percent ratio of mutant NPM1 to ABL1 endogenous control mRNA transcripts."
European regulatory
Xpert® NPM1 Mutation assay
Leica Biosystems strengthens portfolio with FDA clearance of Class II Mismatch Repair (MMR) Panel (PRNewswire)
"Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome."
FDA event
BOND MMR Antibody Panel
OncoMark acquired by US molecular diagnostic company, Cepheid Inc. (University College Dublin)
"University College Dublin (UCD) today formally announced the acquisition of OncoMark Ltd, a UCD spin-out company, by US molecular diagnostics company, Cepheid Inc...OncoMark Ltd developed the OncoMasTR test, based on a panel of genetic drivers of breast cancer."
OncoMasTR test